Has Disc Medicine's 2025 Surge Already Gone Too Far After Pipeline Progress Fuels Rally? [Yahoo! Finance]
Disc Medicine, Inc. (IRON)
Company Research
Source: Yahoo! Finance
Let us unpack what the market might be implying about its future. Despite dipping about 0.2% over the last week, the stock is still up 8.7% over 30 days and has surged roughly 49.9% year to date and 45.6% over the past year, which clearly flags shifting expectations around its growth and risk profile. Those moves have come as investors focus on Disc Medicine's progress in its hematology pipeline, including clinical updates across programs targeting rare blood disorders, and growing attention from larger healthcare investors. Together, these developments are reshaping how the market is thinking about its long term opportunity and downside risk. Even after that rally, Disc Medicine only scores a 2/6 valuation check score , suggesting it screens as undervalued on just a couple of our standard metrics. We will therefore dig into what each method is really telling us and, later on, look at a more nuanced way to think about its true value. Disc Medicine scores just 2/6 on our valuat
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine (NASDAQ:IRON) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- Disc Medicine (NASDAQ:IRON) had its price target raised by analysts at Truist Financial Corporation from $86.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- What Disc Medicine (IRON)'s Bitopertin Fast-Track Review and Rising R&D Spend Mean for Shareholders [Yahoo! Finance]Yahoo! Finance
- Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
IRON
Earnings
- 11/6/25 - Miss
IRON
Sec Filings
- 12/12/25 - Form 144
- 12/12/25 - Form 144
- 12/12/25 - Form 144
- IRON's page on the SEC website